A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Sponsor
Hoffmann-La Roche
Study ID
NCT01562327
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab — DRUG
    Participants received tocilizumab according to individualized physician-prescribed regimens.

Study Details

This multi-center, observational study will evaluate the clinical practice patterns, efficacy and safety of RoActemra/Actemra (tocilizumab) in participants with moderate to severe rheumatoid arthritis. Data will be collected from each eligible participant initiated on RoActemra/Actemra treatment by their treating physician according to local label for 6 months from start of treatment.

Key Dates

Start date
Feb 29, 2012
Status verified
Oct 2016
Primary completion
Mar 31, 2014
Completion
Mar 31, 2014

Study Design

Enrollment
50 participants (actual)

Arms

  • Arm: Tocilizumab
    Participants with moderate to severe rheumatoid arthritis (RA) received Tocilizumab according to individualized physician-prescribed regimens.

Primary Outcome Measure

Percentage of Participants on Tocilizumab Treatment at 6 Months After Treatment Initiation [ Time Frame: 6 months after treatment initiation ]

Related Studies